SciSparc Receives Notification From Nasdaq Regarding Minimum Bid Price Compliance
SciSparc Receives Notification From Nasdaq Regarding Minimum Bid Price Compliance
SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the "Company" or "SciSparc"), today announced it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol "SPRC".
SciSparc有限公司（納斯達克股票代碼：SPRC）是一家專注於開發治療中樞神經系統障礙和罕見疾病的特殊臨床階段藥品公司（以下簡稱“公司”或“SciSparc”），今天宣佈收到了納斯達克證券交易所（“納斯達克”）發出的書面通知（以下簡稱“通知”）。通知表示公司未符合納斯達克規則5550(a)(2)規定的持續上市最低買盤價要求，該規則要求上市證券的最低買盤價維持在每股1.00美元以上。根據納斯達克規則5810(c)(3)(A)，公司獲得了180個日曆日的期限來恢復符合最低買盤價要求。通知對公司的納斯達克上市或其普通股的交易沒有立即影響，在容忍期內（如可能會延長）公司的普通股將繼續在納斯達克交易，交易符號爲“SPRC”。